https://www.selleckchem.com/products/ots514.html
5-year OS (median OS) decreased to 29% (33months) in cN1cM0-pN1(limited) and to 23% (23months) in cN1cM0-pN1(extensive) patients. Those with cM1-pN1 disease had the worst prognosis, with a 5-year OS rate of 13% (9months). On multivariable analysis, age (p = 0.034), tumour size (p = 0.02), grade (p = 0.02) and clinico-pathological group (p 0.05) were significant predictors of ACM. Depending on clinico-pathological group, grade and tumour size, 5-year survival of patients with LN metastases varies from 13 to 43%. Patients with resecte
Like
Comment
Share
